Covered recipient · General Payments record
ANDRE A BONNECAZE
Allopathic & Osteopathic Physicians Internal Medicine
General Payments · PY2018–2024
$2,326.72
- Reported across 125 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,123.23 | 58 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Genentech USA, Inc. | $92.25 | 5 |
| GENZYME CORPORATION | $85.48 | 4 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $77.72 | 4 |
| Merck Sharp & Dohme Corporation | $72.13 | 4 |
| Daiichi Sankyo Inc. | $70.85 | 3 |
| Janssen Biotech, Inc. | $68.54 | 4 |
| Incyte Corporation | $63.26 | 3 |
| ABBVIE INC. | $53.10 | 2 |
| Pharmacosmos Therapeutics Inc. | $50.13 | 3 |
| BeiGene USA, Inc. | $49.90 | 3 |
| Ipsen Biopharmaceuticals, Inc | $45.01 | 2 |
| EISAI INC. | $43.33 | 2 |
| Collegium Pharmaceutical, Inc. | $41.73 | 2 |
| Cumberland Pharmaceuticals, Inc. | $36.02 | 2 |
| PharmaEssentia USA Corporation | $35.52 | 2 |
| Karyopharm Therapeutics Inc. | $34.14 | 2 |
| SOBI, INC | $23.43 | 1 |
| AVEO Pharmaceuticals, Inc. | $23.29 | 1 |
| Acerta Pharma LLC | $21.89 | 1 |
| Gilead Sciences, Inc. | $21.75 | 1 |
| Exelixis Inc. | $18.95 | 1 |
| Regeneron Healthcare Solutions, Inc. | $18.69 | 1 |
| Stemline Therapeutics Inc. | $17.62 | 1 |
| Genmab U.S., Inc. | $16.33 | 1 |
| Takeda Pharmaceuticals U.S.A., Inc. | $14.80 | 1 |
| TAIHO ONCOLOGY, INC. | $13.94 | 1 |
| Mirati Therapeutics, Inc. | $13.43 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (58)
Sorted by paying entity, then date · as published by CMS
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.